ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0171

Associations Between Discrimination Experiences and Patient-Reported Outcomes Among Asian Individuals with Systemic Lupus Erythematosus (SLE)

Patti Katz1, JoonSuk Park2, Kamil Barbour3, Kurt Greenlund3, Maria Dall'Era4 and Jinoos Yazdany2, 1UCSF, San Rafael, CA, 2University of California San Francisco, San Francisco, CA, 3CDC, Alpharetta, GA, 4UCSF, Corte Madera, CA

Meeting: ACR Convergence 2024

Keywords: Patient reported outcomes, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Discrimination experiences have been linked to poor outcomes among Black individuals with SLE.1  Among Asian adults in the general US population, discrimination has been associated with worse psychological and physical health outcomes.2  In spite of higher levels of severity among Asian adults with SLE,3 the impact of discrimination on outcomes in this group has not been examined. We examined the frequency of discrimination experiences and the association between high levels of reported discrimination experiences among Asian adults with SLE in the US and patient-reported outcomes (PROs).

Methods: Data were from Year 5 of the California Lupus Epidemiology Study (CLUES), a longitudinal cohort with rheumatologist-confirmed SLE.  Discrimination experiences were measured with the Everyday Discrimination Scale (EDS), which consists of 10 items rated according to frequency of occurrence and scored 0 (never occurred) to 5 (occurs almost every day).4 PROs examined were PROMIS Physical Function, Pain Interference, and Fatigue; Patient Health Questionnaire (PHQ)-8 (depressive symptoms); Generalized Anxiety Disorder (GAD) questionnaire; and Systemic Lupus Activity Questionnaire (SLAQ, self-reported disease activity). EDS was scored by average item ratings and by tabulating any experience of each type of discrimination. High levels of discrimination were defined as the top quartile of summed EDS scores for the total sample. Characteristics were compared across groups by chi-square analyses and analyses of variance.  Frequency of ever experiencing each type of discrimination was tabulated and compared among racial/ethnic groups with chi-square analyses. Multiple linear regression analyses compared PRO scores between those with high v. lower EDS scores by racial/ethnic group, adjusting for sociodemographic and SLE-related variables.

Results: Participant characteristics (n=245) are shown in Table 1. Experience of discrimination types varied from 15.1% (followed in stores) to 55.2% (people act as if they are better than you are) (Table 2). There were significant differences among racial/ethnic groups on the experience of each type of discrimination. Black participants had the highest discrimination scores. Asian participants reported the highest frequency of being called names and being threatened, the second highest frequency of experiencing 7 of the 8 other types of discrimination, and the second highest summed EDS score (7.7 ± 6.0). Among Asian participants, high discrimination scores were associated with significantly higher depression and anxiety scores and higher self-reported disease activity (Table 3).

Conclusion: Asian adults with SLE experienced substantial levels of discrimination, and in this group, high levels of discrimination were associated with worse mental health and higher self-reported SLE activity. These findings expand previous analyses showing the negative impact of discrimination on Black individuals with SLE and support further exploration of the prevalence and impact of discrimination as a chronic stressor.

1 Chae DH et al. AJPH 2015;105:2099

2 Gee GC et al. Epidemiol Rev 2009;31:130

3 DeQuattro K et al. Arthritis Care Res 2022;74:896

4 Williams DR. Soc Sci Med 2008;67:441

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: P. Katz: None; J. Park: None; K. Barbour: None; K. Greenlund: None; M. Dall'Era: AstraZeneca, 2, Aurinia, 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2; J. Yazdany: AstraZeneca, 2, Aurinia, 5, Bristol-Myers Squibb(BMS), 5, Gilead, 5, UCB, 2.

To cite this abstract in AMA style:

Katz P, Park J, Barbour K, Greenlund K, Dall'Era M, Yazdany J. Associations Between Discrimination Experiences and Patient-Reported Outcomes Among Asian Individuals with Systemic Lupus Erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/associations-between-discrimination-experiences-and-patient-reported-outcomes-among-asian-individuals-with-systemic-lupus-erythematosus-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-discrimination-experiences-and-patient-reported-outcomes-among-asian-individuals-with-systemic-lupus-erythematosus-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology